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To clarify the possible pathogenetic role of oxidation products originated from the glycation of
proteins, human globins from nephropathic patients have been studied by matrix-assisted
laser desorption/ionization mass spectrometry (MALDI), revealing not only unglycated and
monoglycated globins, but also a series of different species. For the last ones, structural
assignments were tentatively done on the basis of observed masses and expectations for the
Maillard reaction pattern. Consequently, they must be considered only propositive, and the
discussion which will follow must be considered in this view. In our opinion this approach
does not seem to compromise the intended diagnostic use of the data because distinctions are
valid even if the assignments are uncertain. We studied nine healthy subjects and 19
nephropathic patients and processed the data obtained from the MALDI spectra using a
multivariate analysis. Our results showed that multivariate analytical techniques enable
differential aspects of the profile of molecular species to be identified in the blood of end stage
nephropathic patients. A correct grouping can be achieved by principal component analysis
(PCA) and the results suggest that several products involved in carbonyl stress exist in
nephropathic patients. These compounds may have a relevant role as specific markers of the
pathological state. (J Am Soc Mass Spectrom 2007, 18, 1018–1023) © 2007 American Society
for Mass SpectrometryThe role of oxidation processes occurring in vivohas been amply discussed in the literature and isconsidered the starting point of various compli-
cations in different diseases. In particular, it becomes
relevant when it occurs on glycated proteins, leading to
the production of dicarbonyl compounds. These species
can react at the tissue level, leading to severe tissue
modifications [1– 4]. Carbonyl stress has been, and still
is, the object of much experimental research devoted to
the structural identification of these reactive com-
pounds with a view to developing possible therapeutic
strategies. Among the potential dicarbonyl compounds,
glyoxal, methylglyoxal, and deoxyglucosone (Figure
1a) levels have been determined in many different
pathological conditions and, in the case of diabetic and
nephropathic patients, their levels were found to be
related to the severity of the pathological condition
[4 –9].Address reprint requests to Dr. Pietro Traldi, CNR-ISTM, Corso Stati Uniti
4, I35100 Padova, Italy. E-mail: pietro.traldi@adr.pd.cnr.it
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doi:10.1016/j.jasms.2007.02.011It is generally believed that these products originate
from glycated proteins via mechanisms generally in-
volving the classic Maillard reaction pattern [10 –13]:
the hexose molecules react with the amino group that is
either terminal or exposed in the protein structure,
undergoing a series of dehydration and oxidation reac-
tions that ultimately lead to the release of reactive
dicarbonyls.
End-stage renal disease can be the outcome of many
different kidney pathologies and is characterized by
severe kidney function impairment. Some pathological
events in end-stage renal disease are the consequences
of an accumulation in the plasma of the so-called
uremic toxins, the nature of which has yet to be fully
clarified. Among these products, the activity of car-
bonyl compounds has recently been emphasized, and
this topic has been an object of many investigations
[1, 2, 5, 14, 15].
Carbonyl compounds, due to their high reactivity, are
believed to be responsible for various types of tissue
damage related to several conditions characteristic of
end-stage disease, e.g., macroangiopathy, dialysis-related
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nonpathological states, these compounds are usually
excreted by the kidney, but in the case of severe kidney
disease their excretion is impaired, leading to what is
called “carbonyl stress” [10, 19 –23].
Previous investigations of human globins performed
by MALDI mass spectrometry [24 –29] were devoted
mainly to ascertaining the significance of glycated he-
moglobin (HbA1c), a specific subtype of hemoglobin A,
formed by the binding of glucose to the hemoglobin
molecule. Since HbA1c degradation proceeds relatively
slowly, the blood level of HbA1c represents the average
blood glucose levels of about the past four weeks. The
amount of this glycated hemoglobin is used in clinics as
an indicator of the average glucose blood levels, and
may also suggest the amount of glycation-linked dam-
age to tissues. MALDI mass spectrometry showed that
many globin species are expressed by healthy and
diabetic subjects [26 –29]. Apart from the peaks related
to unglycated and monoglycated - and -globins,
numerous other different ionic species were identified
by MALDI MS, including some glycoxidation products,
reflecting the subject’s oxidative stress. These studies
also proved that the HbA1c values, usually evaluated by
HPLCmethods or with electrospray mass spectrometric
methods (LC/ESI/MS), [30] are not linearly related
Figure 1. (a) Molecular structures of glyoxal, m
of protein with hydroxymethyl furane moiety.
Table 1. Clinical characteristics of the patients under study (me
Gender
Age
(years)
Dialysis
duration
(months)
F
Nephropathic
patients
F(9); M(10) 15.6  7.8 21.35  12.3 7
Healthy
controls
F(4); M(5) 16.4  5.9 — 8
*P 0.001, Student’s t-test: calculated for nephropathic patients versus he
aFasting plasma glucose has been obtained by a glucose-oxidase meth
bHbA1c was measured by LC method, routinely used in clinical laboratory.
c,dWere evaluated by standard clinical analysis.with the -globin glycation level (as is generally as-
sumed), but do correlate well with the whole pool of
glycated and glycoxidated species detected by
MALDI/MS [28, 29].
To clarify the question whether of oxidation prod-
ucts originated from the glycation of proteins survive
on the protein frame or, once formed, are released from
the protein, leading to the production of dicarbonyl
compounds, we thought it may be of interest to evalu-
ate the level of these substances in blood samples.
Hence, our interest in the analytical data obtained by
MALDI for a series of blood samples from nephropathic
subjects, which we compared with the data obtained in
healthy controls.
Materials and Methods
Subjects
Nineteen patients with chronic renal failure and nine
normal controls were evaluated. Their clinical and
metabolic characteristics are shown in Table 1. Ten of
the nephropathic patients were on hemodialysis and
nine were on peritoneal dialysis. All patients had been
in stable clinical condition for six months before the
study. Exclusion criteria were: malnutrition, smoking,
glyoxal, and 3-deoxyglucosone and (b) structure
SD)
g plasma
cosea
g/dl) HbA1c
b (%)
Blood
nitrogenc
(mmol/L)
Blood
creatinined
(mol/L)
 20.76 5.10  0.67 18.58  6.56* 691.56  250.12*
 17.73 4.84  1.18 5.64  3.47 57.67  15.64
controls. The difference is statistically significative only in these cases.
outinely used in clinical laboratory.ethylan 
astin
glu
(m
6.11
2.96
althy
od, r
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diseases. All subjects gave their informed consent to the
study, which was approved by the local Ethics Com-
mittee and was conducted in accordance with the
Helsinki Declaration of 1975.
Methods
Fresh blood samples were diluted 1:50 in water and
frozen until MALDI analysis. The samples were then
diluted 1:10 with a 0.1% trifluoroacetic acid aqueous
solution. The matrix solution was prepared by dissolv-
ing 10 mg of 2,6-dihydroxyacetophenone (DHAP)
(Fluka, Buchs, CH) in 1 mL of 1:1 (vol/vol) ethanol/
acetonitrile with the addition of 100 L of 1M aqueous
solution of diammonium hydrogen citrate (DHAC)
(Fluka). These solutions were vortexed before use. Sam-
ples were prepared by mixing equal volumes of matrix
and sample solutions, applying 1 L to a stainless steel
sample holder and allowing it to dry before mass
spectrometric analysis.
MALDI spectra were obtained on a Voyager-DE
PRO instrument (Applied Biosystems, Foster City, CA),
working in positive linear mode. The target was irradi-
ated with a 337 nm pulsed nitrogen laser. Ions were
accelerated to 25.0 keV kinetic energy. The working
conditions for the extraction delay were: grid voltage
92%; guide wire  0.15%; extraction delay time  300
ns. Mass spectra were obtained by averaging 50 laser
shots; three separate MALDI measurements were taken
for each sample to establish their reproducibility.
Data Treatment and Statistical Analysis
MALDI-MS data in the range 15 to 16.4 kDa on the
whole-blood samples of patients and healthy controls
were inserted into a spreadsheet and sorted by m/z
values. The abundance of the different compounds
arising from glycation and glyco-oxidation processes of
- and -globins, whose identification and structures
have been assigned on the basis of the Maillard reaction
pattern, have been expressed as relative abundance of
the corresponding globin peak, kept equal to 100. The
renormalization of the spectrum so obtained has a
chemical meaning; in fact - and -globins, being the
two separated portion of the same precursor, must be
present in molar ratio 1:1 and the difference observed in
the abundance of their MALDI peaks is due to a
different ionization yield of the two proteins. The data
from all the subjects were converted to ASCII files by
using the SpecAlign software, developed by Dr. Jason
W. H. Wong, Chemistry Department, Physical and
Theoretical Chemistry Laboratory, Oxford University,
U.K. The software characteristics have been described
elsewhere by Wong et al. [31]; for the present study,
version 1.22b r2 was used. Briefly, the software offers a
graphical computational tool that enables simultaneous
visualization and manipulation of multiple datasets;
data implementation in a matrix suitable for furtherstatistical analysis is easily possible as well as the
binning of data according to a specified value; a base-
line subtraction tool is also available.
The spectra were pretreated, considering only ionic
species with abundance detectable over the background
signal. The 15 most intense peaks across all 28 spectra
(from 19 patients and nine controls) were tabulated
(allowing an uncertainty of 5 m/z in the peak posi-
tions) and their intensities collected into a 15  28
matrix. The maximum intensities within each bin were
used to represent the intensity noted for that bin. Data
processed in ASCII format were imported into an Excel
spreadsheet and used for statistical evaluation. Further
details on the spectra data handling can be found in the
documentation of SpecAlign program [31].
Multivariate Analysis
Cluster analysis. Cluster analysis is a multivariate pro-
cedure of exploratory data analysis for detecting natu-
ral groupings in data and examining similarities and
dissimilarities between observations. The pattern of
globin glycoxidation products in patients and controls
was analyzed by using a clustering procedure without
any prior knowledge of grouping (unsupervised clus-
tering) to find criteria useful in differentiating between
the cases. Data were analyzed using AMADA software
[32] using the K-means partition algorithm proposed by
J. Hartigan [33], which splits a set of data into a selected
number of groups by minimizing the sum of the
squares of the distances between the data and the
corresponding cluster centroid (average of the cluster
members’ coordinates). K-means is a clustering tech-
nique that works well if compared to hierarchical
methods, and is less affected by outliers; the algorithm
classifies data based on their features into k number of
groups, k being a positive integer. The distances were
measured with Spearman’s rank correlation coefficient
or Euclidean distance. In some cases, data dimension-
ality was reduced by correspondence analysis, a statis-
tical ordination method, somewhat similar to principal
component analysis (PCA, see below), allowing analy-
sis of large contingency tables [34].
Principal component analysis (PCA). PCA is a mathe-
matical procedure that reduces a large set of variables to
a small set containing most of the original information.
The reduced set contains what are called principal
factors, which are linear combinations of the original
variables. The first principal component accounts for as
much of the variability in the data as possible, and each
succeeding component accounts for the remaining vari-
ability. PCA can help identify new, meaningful under-
lying variables and can also detect clusters within
multivariate data. PCA was done using the AMADA
software on the matrix of m/z values for all patients and
controls (like cluster analysis), using a covariance ma-
trix and standardized principal component scores. The
first three components were considered for data classi-
1021J Am Soc Mass Spectrom 2007, 18, 1018–1023 GLYCOXIDATED GLOBINS IN NEPHROPATHIESfication. A 3D-scatter plot was obtained with the Gnu-
plot 4.0 program, a freely distributed interactive data
and function plotting utility for several platforms, writ-
ten by Thomas Williams, Colin Kelley, et al.;
http://www.gnuplot.info/index.html.
Results and Discussion
The typical MALDI spectra of the globin fraction in the
range of 15 to 16.4 kDa from a healthy subject and an
end-stage renal disease patient are shown in Figure 2a
and b, respectively. Some differences can be observed
from a visual inspection of the spectra. The two most
abundant peaks at m/z 15,126 and 15,866 are due to
protonated - and -globins, respectively, but a number
of other peaks are detectable. Some of them, e.g., those
at m/z 15,148 and 15,888, do not represent different
molecular species, but derive from Na cationization of
the two globins. The presence of glycated globins is
clear, however, from the presence of the related peaks:
the ion at m/z 15,288 represents the protonated glycated
-globin, while the one at m/z 16,028 is due to proton-
ated glycated -globin. The structural assignments
were tentatively done on the basis of observed masses
and expectations for the Maillard reaction pattern.
Consequently, they must be considered only proposi-
tive and the discussion that will follow must be consid-
ered in this view. In our opinion, this approach does not
seem to compromise the intended diagnostic use of the
data because distinctions are valid even if the assign-
ments are uncertain. Further ions may derive from
oxidation-dehydration processes occurring on the gly-
cated proteins; e.g., for the ion at m/z 15,223 these
Figure 2. Typical MALDI spectra of the globin fraction from a
healthy subject (a) and a nephropathic patient (b).processes lead to hydroxymethylfuran. In other words,these ionic species might be consistent with glycated
-globin, which -through dehydration and oxidation
taking place on the sugar moiety – might leads to
hydroxymethylfurane-containing species (Figure 1b).
The tall peak at m/z 15,182 observed in the case of a
nephropathic patient (Figure 2b) might be consistent
with the presence of glyoxal-containing species (Figure
1a). The analogous species is detected for -globin at
m/z 15,922. It is worth noting that the patients’ spectra
have more numerous and more abundant glycoxidated
species, suggesting that more oxidation/dehydration
might occur on glycated species in kidney disease.
The critical evaluation of the differences between
MALDI spectra of - and -globins present in blood
samples of healthy subjects and patients is a quite
difficult task and consequently a multivariate analysis
of the data were considered of interest.
The MALDI data of all healthy and nephropathic
subjects were processed by multivariate analysis using
two different approaches: one considered all species
detected in the spectra, while the other excluded the
data pertaining to unglycated or simply glycated - and
-globins. When the k-means clustering algorithm was
applied to the spectra according to two grouping crite-
ria, a clear differentiation between patients and controls
was obtained for both including (Figure 3) and exclud-
ing (data not shown) glycated and unglycated - and
Figure 3. K-means cluster analysis of all species (after reducing
data dimensionality with correspondence analysis) in the MALDI
spectra of nephropathic patients (numbered as p1 to p19) and
healthy controls (numbered as c1 to c9). The k number of clusters
was set to 2 and Euclidean distance was used for metering. A
similar grouping was also achieved with the spectra without
glycated and unglycated - and -globins.
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spectral data, the algorithm again presented one com-
pact cluster containing all the controls, and the patients
divided unevenly between the other two clusters, re-
gardless of whether or not the data included glycated
and unglycated - and -globins (data not shown).
Extending the grouping criteria to four clusters applied
to the whole spectra (Figure 4a) bundled the data of the
controls into a single group, while the data of the
patients were distributed among the other three clus-
ters. After excluding the values for glycated and ung-
lycated - and -globins, the clustering algorithm ac-
cording to four grouping criteria led to a split in both
the controls’ and the patients’ data (Figure 4b).
The results of the clustering procedure indicate that
the MALDI pattern of the spectra can clearly differen-
tiate patients from controls. As suggested by the cluster
dendrogram obtained including peaks attributed to
glycated and unglycated - and -globins (Figure 3),
the contribution of these species in the spectrum ap-
peared to have little diagnostic value in discriminating
healthy subjects from nephropathic patients, whereas
the pool of glycoxidated species can make this
distinction.
Honing the clustering criteria, further differences
relating to the glycoxidation products emerge in the
patients’ data that might be related to the severity of
their disease and/or their reactive status. Excluding
glycated and unglycated - and -globins from the
cluster analysis made the patient group more homoge-
nous, suggesting that the behavior of the globins helps
to distinguish between patients, but not to separate
patients from controls.
PCA confirmed the grouping of patients and con-
trols. The 3D plots of the first three principal compo-
nents are shown in Figure 5 and Figure 6. When all the
species of the MALDI spectra are considered, the pa-
tients’ data were quite scattered (Figure 5), but clearly
distinguishable from the control group. Excluding the
glycated and unglycated globins, the patients’ data
Figure 4. K-means cluster analysis of the whole species in the
MALDI spectra of nephropathic patients (numbered as p1 to p19)
and healthy controls (numbered as c1 to c9). The k number of
clusters was set to 4 and Spearman’s distance was used for
metering. Graph (a) included and graph (b) excluded glycated and
unglycated - and -globins.were more concentrated in a specific region of the
principal component space (Figure 6). It is worth noting
that the controls were well grouped in both analytical
conditions, irrespective of the glycated and unglycated
- and -globins. The first three components of PCA
explained as much as 78% of the total variance among
the data, when excluding the globin species, and 71%
when including also globin species.
It is worth noting that these procedures are unsuper-
vised, i.e., they are left free to find an aggregating
criterion just on the general behavior of the native data;
the results obtained, therefore, support the existence of
a real capacity of the spectra to differentiate between
pathological and healthy conditions.
In conclusion, the multivariate analysis used here
proved capable of identifying differential aspects of the
profile of ionic species from globins of end-stage ne-
phropathic patients. The point to make is that a correct
grouping can be achieved even excluding the glycated
Figure 5. 3D plot of the first three components resulting from the
PCA of the whole MALDI spectra of patients and controls,
including glycated and unglycated - and -globins. The ovals
indicate the regions of the principal component space presenting
data of the two groups.
Figure 6. 3D plot of the first three components resulting from the
PCA of the MALDI spectra of patients and controls, without
glycated and unglycated - and -globins. The ovals indicate the
regions of the principal component space presenting data of the
two groups.
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as well as cluster analysis. Our data are also consistent
with those of Antolini et al. [23], who suggested that
PCA on oxidative stress parameters can discriminate
between hemodialysis patients, transplanted patients,
and controls. Our findings suggest that several prod-
ucts involved in the carbonyl stress are present in
nephropathic patients, and that these compounds may
have a relevant role as specific markers of the disease,
even though they are detectable in low amounts.
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